AI in Oncology Takes Off, Tackling HIV and Liver Disease, Pharma’s Recent Gains
About this episode
The episode discusses the latest advancements in AI for oncology, HIV research using CRISPR, and recent pharmaceutical acquisitions.
Some GEN editors were in sunny San Diego covering the hottest research, trends, and products from the American Association for Cancer Research meeting. We kick things off with news from America’s Finest City, particularly around the growing role of AI in oncology. Then we dive into two new research studies. In the first, scientists used CRISPR to identify genes in primary CD4+ T cells that promote or restrict HIV infection. The second study described engineered implantable liver constructs that could eventually serve as a stopgap for patients waiting for donor transplants. Finally, the acquisitions keep coming as Eli Lilly scoops up CAR T cell therapy developer Kelonia for $7B. Also, Revolution Medicines has shared some impressive data from a Phase III trial of its pancreatic cancer drug. Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base : AACR 2026: A Video Update from San Diego By Julianna LeMieux, PhD, and Damian Doherty, GEN , April 21, 2026 AACR 2026 Video…
More episodes of Touching Base
- Drugs from a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
- Agentic AI, Virtual Cell, LNP Vaccine Boosters, Engineered Organs, and Mergers
- Bacteria 4D Simulation, Safer Large Gene Insertion, uniQure Roller Coaster
- AI for Scientists, FDA Reverses Course, and Advances in Cancer Therapeutics
- Women in Science, Robotics, Automation, SLAS, and Lilly Updates
- Ex-CEO Behind Bars, 10x’s Clinical Ambitions, and Pharma’s AI Gambit
Explore listener stats, chart rankings, contacts and more on the Touching Base podcast page.